Phase 1 study of the BRAF inhibitor dabrafenib (D) with or without the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation positive unresectable or metastatic melanoma (MM)

被引：41
|
作者：
Puzanov, Igor
Callahan, Margaret K.
Linette, Gerald P.
Patel, Sapna Pradyuman
Luke, Jason J.
Sosman, Jeffrey Alan
Wolchok, Jedd D.
Hamid, Omid
Minor, David R.
Orford, Keith W.
Hug, Bruce A.
Ma, Bo
Matthys, Gemma M.
Hoos, Axel
机构：
[1] Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Nashville, TN 37212 USA
[2] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[3] Washington Univ, Sch Med, Div Oncol, St Louis, MO USA
[4] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[5] Dana Farber Canc Inst, Boston, MA 02115 USA
[6] Angeles Clin & Res Inst, Los Angeles, CA USA
[7] Calif Pacific Med Ctr, Res Inst, San Francisco, CA USA
[8] GlaxoSmithKline, Res & Dev, Collegeville, PA USA
[9] GlaxoSmithKline, Res & Dev, Res Triangle Pk, NC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.2511
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2511
引用
收藏
页数：1
相关论文
共 50 条
  • [41] COMBI-v: health-related quality of life (HRQoL) impact of the combination of dabrafenib and trametinib (D plus T) vs vemurafenib (V) in patients with BRAF V600 metastatic melanoma (MM)
    Grob, J. J.
    Amonkar, M.
    Karaszewska, B.
    Schachter, J.
    Dummer, R.
    Mackiewicz, A.
    Stroiakovski, D.
    Drucis, K.
    Grange, F.
    Chiarion-Sileni, V.
    Rutkowski, P.
    Lichinitser, M.
    Levchenko, E.
    Wolter, P.
    Hauschild, A.
    Long, G. V.
    Sun, P.
    McDowell, D. O.
    Mookerjee, B.
    Robert, C.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S682 - S683
  • [42] Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma
    Schadendorf, Dirk
    Amonkar, Mayur M.
    Stroyakovskiy, Daniil
    Levchenko, Evgeny
    Gogas, Helen
    de Braud, Filippo
    Grob, Jean-Jacques
    Bondarenko, Igor
    Garbe, Claus
    Lebbe, Celeste
    Larkin, James
    Chiarion-Sileni, Vanna
    Millward, Michael
    Arance, Ana
    Mandala, Mario
    Flaherty, Keith T.
    Nathan, Paul
    Ribas, Antoni
    Robert, Caroline
    Casey, Michelle
    DeMarini, Douglas J.
    Irani, Jhangir G.
    Aktan, Gursel
    Long, Georgina V.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 (07) : 833 - 840
  • [43] Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study (vol 28, pg 1631, 2017)
    Long, G. V.
    Flaherty, K. T.
    Stroyakovskiy, D.
    Gogas, H.
    Levchenko, E.
    de Braud, F.
    Larkin, J.
    Garbe, C.
    Jouary, T.
    Hauschild, A.
    Chiarion-Sileni, V.
    Lebbe, C.
    Mandala, M.
    Millward, M.
    Arance, A.
    Bondarenko, I.
    Haanen, J. B. A. G.
    Hansson, J.
    Utikal, J.
    Ferraresi, V.
    Mohr, P.
    Probachai, V.
    Schadendorf, D.
    Nathan, P.
    Robert, C.
    Ribas, A.
    Davies, M. A.
    Lane, S. R.
    Legos, J. J.
    Mookerjee, B.
    Grob, J. -J.
    ANNALS OF ONCOLOGY, 2019, 30 (11) : 1848 - 1848
  • [44] Cost-Effectiveness Analysis of Dabrafenib Plus Trametinib and Vemurafenib as First-Line Treatment in Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma in China
    Gao, Tianfu
    Liu, Jia
    Wu, Jing
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2021, 18 (12)
  • [45] Five-year overall survival (OS) update from a phase II, open-label trial of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600-mutant unresectable or metastatic melanoma (MM).
    Long, Georgina V.
    Eroglu, Zeynep
    Infante, Jeffrey R.
    Patel, Sapna Pradyuman
    Daud, Adil
    Johnson, Douglas Buckner
    Gonzalez, Rene
    Kefford, Richard
    Hamid, Omid
    Schuchter, Lynn Mara
    Cebon, Jonathan S.
    Sharfman, William Howard
    McWilliams, Robert R.
    Sznol, Mario
    Weber, Jeffrey S.
    Mookerjee, Bijoyesh
    Gasal, Eduard
    Redhu, Suman
    Flaherty, Keith T.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [46] An open-label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib for patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma
    Saiag, P.
    Robert, C.
    Grob, J. J.
    Mortier, L.
    Dereure, O.
    Lebbe, C.
    Mansard, S.
    Grange, F.
    Neidhardt, E-M.
    Lesimple, T.
    Machet, L.
    Bedane, C.
    Jeudy, G.
    Aubin, F.
    Dreno, B.
    Szenik, A.
    Denden, A.
    Dutriaux, C.
    ANNALS OF ONCOLOGY, 2018, 29
  • [47] COMBI-MB: A phase II study of combination dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600-mutant (mut) melanoma brain metastases (MBM).
    Davies, Michael A.
    Robert, Caroline
    Long, Georgina V.
    Grob, Jean Jacques
    Flaherty, Keith T.
    Arance, Ana
    Chiarion-Sileni, Vanna
    Thomas, Luc
    Lesimple, Thierry
    Mortier, Laurent
    Moschos, Stergios J.
    Hogg, David
    Rodas, Ivan Marquez
    Del Vecchio, Michele
    Lebbe, Celeste
    Meyer, Nicolas
    Zhang, Ying
    Huang, Yingjie
    Mookerjee, Bijoyesh
    Saiag, Philippe
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [48] An update on BREAK-3, a phase III, randomized trial: Dabrafenib (DAB) versus dacarbazine (DTIC) in patients with BRAF V600E-positive mutation metastatic melanoma (MM)
    Hauschild, Axel
    Grob, Jean Jacques
    Demidov, Lev V.
    Jouary, Thomas
    Gutzmer, Ralf
    Millward, Michael
    Rutkowski, Piotr
    Blank, Christian U.
    Miller, Wilson H.
    Kaempgen, Eckhart
    Martin-Algarra, Salvador
    Karaszewska, Boguslawa
    Mauch, Cornelia
    Chiarion-Sileni, Vanna
    Mirakhur, Beloo
    Guckert, Mary E.
    Swann, R. Suzanne
    Haney, Patricia
    Goodman, Vicki L.
    Chapman, Paul B.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [49] Pembrolizumab (pembro) in combination with dabrafenib (D) and trametinib (T) for BRAF-mutant advanced melanoma: Phase 1 KEYNOTE-022 study
    Ribas, Antoni
    Hodi, F. Stephen
    Lawrence, Donald P.
    Atkinson, Victoria
    Starodub, Alexander
    Carlino, Matteo S.
    Fisher, Rosalie Anne
    Long, Georgina V.
    Miller, Wilson H.
    Huang, Yingjie
    Diede, Scott J.
    Ebbinghaus, Scot
    Hamid, Omid
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [50] Phase 2 study of neoadjuvant dabrafenib plus trametinib (D plus T) for resectable stage IIIB/C BRAF V600 mutant melanoma
    Menzies, A. M.
    Gonzalez, M.
    Guminski, A.
    Nieweg, O.
    Shannon, K.
    Thompson, J. F.
    Kefford, R.
    Ch'Ng, S.
    Stretch, J.
    Spillane, A. J.
    Lee, J.
    Lee, H.
    Kapoor, R.
    Emmett, L.
    Rizos, H.
    Saw, R. P.
    Scolyer, R. A.
    Long, G. V.
    ANNALS OF ONCOLOGY, 2017, 28
12345